[CAS NO. 18642-23-4] Psoralidin

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [18642-23-4]

Catalog

HY-N0232

Brand

MCE

CAS

18642-23-4

DESCRIPTION [18642-23-4]

Overview

MDL	MFCD10566617
Molecular Weight	336.34
Molecular Formula	C20H16O5
SMILES	O=C1C2=C(OC3=CC(O)=CC=C32)C4=CC(C/C=C(C)\C)=C(O)C=C4O1

For research use only. We do not sell to patients.

2 Publications Citing Use of MCE

Summary

Psoralidin is a dual inhibitor of COX-2 and 5-LOX , regulates ionizing radiation (IR)-induced pulmonary inflammation.Anti-cancer, anti-bacterial, and anti-inflammatory properties ^[1] . Psoralidin significantly downregulates NOTCH1 signaling. Psoralidin also greatly induces ROS generation ^[2] .

IC50 & Target

COX-2

5-LOX

In Vitro

Three breast cancer cell (BCC)populations (ALDH ^- cells, ALDH ⁺ cells, and commercial BSCSs) are sensitive to Psoralidin treatment (10, 15, 20, and 25 μM; 24 hours) with IC ₅₀ s ranging from 18 to 21 μM; however, the MCF-12A cells were resistant to Psoralidin ^[2] .
Psoralidin (30 μM; 24 hours) results in a significant induction of apoptosis for ALDH ^- cells, ALDH ⁺ cells, and commercial BCSCs ^[2] .
Psoralidin treatment also downregulates NOTCH1 expression in both ALDH ^- and ALDH ⁺ cells ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay ^[2]

Cell Line:	ALDH ^- cells, ALDH ⁺ cells, commercial breast cancer stem cells (BSCSs), and normal breast epithelial cells (MCF-12A)
Concentration:	10, 15, 50, and 25 μM
Incubation Time:	24 hours
Result:	IC ₅₀ s of 18 to 21 μM for ALDH ^- cells, ALDH ⁺ cells, commercial BCSCs.

Apoptosis Analysis ^[2]

Cell Line:	ALDH ^- cells, ALDH ⁺ cells, and commercial BCSCs
Concentration:	20 and 30 μM
Incubation Time:	24 hours
Result:	No significant induction of apoptosis was observed for any of the three cell types following treatment at 20 μM. However, 53.60%, 44.1%, and 45.9% of cells were apoptotic at 30 μMin ALDH ^- cells, ALDH ⁺ cells, and commercial BCSCs, respectively.

In Vivo

Psoralidin (5 mg/kg) regulates expression of pro-inflammatory cytokines that play an important role in inflammatory diseasesin IR-irradiated lung of BALB/c mouse ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	BALB/c mice ^[1]
Dosage:	5 mg/kg
Administration:	Intraperitoneal application; 30 min before and 1 h after IR irradiation (20 Gy).
Result:	Anti-inflammatory effect in IR-irradiated mice.

Appearance

Solid

Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL ( 148.66 mM ; ultrasonic and warming and heat to 60°C)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.9732 mL	14.8659 mL	29.7318 mL
5 mM	0.5946 mL	2.9732 mL	5.9464 mL
10 mM	0.2973 mL	1.4866 mL	2.9732 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: 2.08 mg/mL (6.18 mM); Suspended solution; Need ultrasonic
2.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.08 mg/mL (6.18 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

6H-Benzofuro[3,2-c][1]benzopyran-6-one, 3,9-dihydroxy-2-(3-methyl-2-buten-1-yl)-

6H-Benzofuro[3,2-c][1]benzopyran-6-one, 3,9-dihydroxy-2-(3-methyl-2-butenyl)-

Psoralidin

3-Benzofurancarboxylic acid, 2-[2,4-dihydroxy-5-(3-methyl-2-butenyl)phenyl]-6-hydroxy-, δ-lactone

3,9-Dihydroxy-2-(3-methyl-2-buten-1-yl)-6H-benzofuro[3,2-c][1]benzopyran-6-one

3,9-Dihydroxy-2-(3-methylbut-2-enyl)-[1]benzofuro[3,2-c]chromen-6-one